GlassScriptPhysician profile
Natalie S Macdonald
NPI 1730429994
$8,484.80
in general payments reported to CMS, 2019-2025
39 companies · $2,459 in 2025
The $2,459 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $981 · 2023: $2,282 · 2024: $2,510 · 2025: $2,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,201 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,200.68 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,095.98 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,093.58 | 2022-2025 | |
| Lilly USA, LLC | $899.65 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $848.54 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $749.58 | 2022-2025 | |
| Pfizer INC. | $499.61 | 2023-2025 | |
| Glaxosmithkline, LLC. | $421.25 | 2022-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Exact Sciences Corporation | $247.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $231.62 | 2023-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.17 | 2022-2025 | Jardiance |
| Dexcom, INC. | $198.27 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $174.45 | 2023-2025 | Voquezna |
| Avanir Pharmaceuticals, INC. | $144.27 | 2021-2022 | |
| Axsome Therapeutics, INC. | $143.06 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.62 | 2023-2025 | Xifaxan |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Macdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.